A Comparison of Three Extrusion Systems (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems (Part II)
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 56-61

References

1. A. Désiré et al., Pharm. Technol. 35 (1), 56–65 (2011).

2. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

3. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).

4. G. Tomer, F. Podczeck, and J.M. Newton, Int. J. Pharm. 231 (1), 248–257 (2002).

5. J.J. Sousa et al., Int. J. Pharm. 232 (1–2), 91–106 (2002).

6. J. Chatchawalsaisin, F. Podczeck, and J.M. Newton, Eur J Pharm Sci. 24 (1), 35–48 (2005).

7. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

8. F.O. Costa, A.A.C.C. Pais, and J.J.S., Int. J. Pharm. 270 (1–2), 9–19 (2004).

9. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

10. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

11. L. Alvarez et al., Eur. J. Pharm. Biopharm. 55 (3), 291–295 (2003).

12. R. Gandhi et al., Pharm. Technol. 29 (2). 68–86 (2005).

13. L. Rahman et al., STP Pharm. Sci. 1 (5), 294–299 (1991).

14. E. Nürnberg, and J. Wunderlich, Pharm. Technol. Eur. 11 (3), 30-34 (1999).

15. S. Galland, T. Ruiz, and M. Delalonde, Int. J. Pharm. 337 (1–2), 239–245 (2007).

16. S. Galland, T. Ruiz, and M. Delalonde, Powder Technol. 190 (1–2), 48–52 (2009).

17. J.F. Pinto and C.N. Abreu, Drug. Dev. Ind. Pharm. 32 (9), 1067–1078 (2006).

18. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 197–204 (1993).

19. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 205–216 (1993).

20. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 217–223 (1993).

21. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2), 205–214 (1997).

22. V.R. Sinha et al., AAPSPharmSciTech, 8 (1), E1–E5 (2007).

23. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

24. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

25. E.I. Hamedelniel, J.Bajdik, and K.Pintye-Hódi, Chemical Engineering and Processing: Process Intensification 49 (1), 120–124 (2010).

26. A. Häring, K. Krejcova, and M. Rabiskova, Farm. Vestn. 54 (special issue), 437–438 (2003).

27. L. Baert et al., Int. J. Pharm. 86 (2–3), 187–192 (1992).

28. L. Baert et al., Int. J. Pharm. 99 (1), 7–12. (1993).

29. C. Schmidt, H. Lindner, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 44 (2), 169–176 (1997).

30. K. Thoma and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 401–411 (1998).

31. K. Thoma, and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 413–422 (1998).

32. D. Sonaglio, B. Bataille, and M. Jacob, Pharm. Acta Helv. 72 (2), 69–74 (1997).

33. C. Schmidt, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 45 (2), 173–179 (1998).

34. J.M. Newton, S.R. Chapman, and R.C. Rowe, Int. J. Pharm. 120 (1), 101–109 (1995).

35. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

36. P. Costa and J.M. Sousa Lobo, Eur. J. Pharm. Sci. 13 (2), 123–133 (2001).

37. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

38. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

39. A.B. Bashaiwoldu, F. Podczeck and J.M. Newton, Eur. J. Pharm. Sci. 21 (2–3), 119–129 (2004).

40. B. Song, S.L. Rough, and D.I. Wilson, Int. J. Pharm. 332 (1–2), 38–44 (2007).

41. J.P. Perez and M. Rabiskova, Int. J. Pharm. 242 (1–2), 349–351 (2002).

42. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

43. J. Berggren and G. Alderborn, Int. J. Pharm. 219 (1–2), 113–126 (2001).

44. P. Kleinebudde, Int. J. Pharm. 109 (3), 209–219 (1994).

45. P. Kleinebudde, Int. J. Pharm. 109 (3), 221–227 (1994).

46. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

47. K. Ligarski et al., STP Pharma Sci. 1 (4), 256–261 (1991).

48. B. Bataille et al., Drug Dev. Ind. Pharm. 19 (6), 653–671 (1993).

49. K. Umprayn, P. Chitropas, and S. Amarekajorn, Drug Dev. Ind. Pharm. 25 (1), 45–61 (1999).

Citation: When referring to this article, please cite it as "Amelie Desire, Bruno Paillard, Joel Bougaret, Michel Baron, Guy Couarraze, "A Comparison of Three Extrusion Systems (Part II)," Pharmaceutical Technology 35 (6) 56-61(2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here